LeMaitre Vascular Inc (LMAT)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $1.79B
Last updated: Nov 17, 2026 at 11:06 AM ET
LeMaitre Vascular Inc (LMAT) Financials: Revenue, Profit and Cash Flow
LeMaitre Vascular reported revenue of $249.60M for the fiscal year ended Dec 31, 2025, up 13.5% from the year before. That year, net income was $57.73M with a net margin of 23.1%, operating cash flow was $81.25M and free cash flow was $74.47M. The quarter ended Sep 30, 2026 had revenue of $67.97M and net income of $15.02M.
Revenue and Margins
The operating margin was 27.2% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $89.15M, a compound annual rate of 12.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $249.60M | +13.5% | 71.5% | 27.2% | 23.1% |
| Dec 2024 | $219.86M | +13.6% | 68.6% | 23.8% | 20.0% |
| Dec 2023 | $193.48M | +19.7% | 65.7% | 19.0% | 15.6% |
| Dec 2022 | $161.65M | +4.7% | 64.9% | 16.6% | 12.8% |
| Dec 2021 | $154.42M | +19.4% | 65.7% | 23.6% | 17.4% |
| Dec 2020 | $129.37M | +10.4% | 65.4% | 22.3% | 16.4% |
| Dec 2019 | $117.23M | +11.0% | 68.1% | 18.1% | 15.3% |
| Dec 2018 | $105.57M | +4.7% | 70.0% | 26.7% | 21.7% |
| Dec 2017 | $100.87M | +13.1% | 70.1% | 20.9% | 17.0% |
| Dec 2016 | $89.15M | N/A | 70.6% | 18.3% | 11.9% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 31.1% from the year before. In the quarter ended Sep 2026, net income fell 13.5% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $249.60M | $219.86M | $193.48M | $161.65M | $154.42M | $129.37M | $117.23M | $105.57M | $100.87M | $89.15M |
| Cost of revenue | $71.06M | $68.96M | $66.44M | $56.76M | $53.04M | $44.75M | $37.38M | $31.63M | $30.17M | $26.21M |
| Gross profit | $178.54M | $150.90M | $127.05M | $104.90M | $101.38M | $84.62M | $79.85M | $73.94M | $70.70M | $62.94M |
| Research and development | $14.14M | $15.65M | $16.97M | $13.29M | $11.80M | $10.10M | $9.28M | $8.20M | $6.64M | $6.14M |
| Operating income | $67.91M | $52.26M | $36.71M | $26.83M | $36.42M | $28.79M | $21.18M | $28.21M | $21.10M | $16.34M |
| Net income | $57.73M | $44.04M | $30.11M | $20.64M | $26.91M | $21.22M | $17.93M | $22.94M | $17.18M | $10.59M |
| EBITDA | $78.56M | $61.80M | $45.91M | $35.94M | $47.38M | $36.85M | $26.40M | $32.14M | $25.00M | $19.77M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.97M | $70.38M | $66.55M | $64.45M | $61.05M | $64.23M | $59.87M | $55.72M | $54.82M | $55.85M | $53.48M | $48.88M |
| Gross profit | $48.70M | $50.76M | $48.40M | $46.19M | $45.95M | $44.97M | $41.42M | $38.59M | $37.18M | $38.47M | $36.66M | $33.27M |
| Operating income | $17.70M | $20.40M | $17.77M | $18.83M | $20.31M | $16.14M | $12.63M | $12.85M | $13.15M | $14.38M | $11.87M | $10.21M |
| Net income | $15.02M | $17.05M | $15.68M | $15.58M | $17.36M | $13.78M | $11.01M | $11.18M | $11.14M | $11.83M | $9.89M | $8.46M |
Balance Sheet
As of Dec 2025, total debt of $171.59M exceeded cash and equivalents by $143.34M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $615.69M | $551.82M | $346.78M | $310.48M | $292.80M | $252.81M | $188.34M | $153.09M | $126.32M | $101.92M |
| Current assets | $468.23M | $402.19M | $194.60M | $161.73M | $139.88M | $94.26M | $92.09M | $94.02M | $80.31M | $59.03M |
| Cash and equivalents | $28.24M | $25.61M | $24.27M | $19.13M | $13.86M | $26.76M | $11.79M | $26.32M | $19.10M | $24.29M |
| Total liabilities | $222.17M | $214.53M | $48.88M | $42.27M | $38.65M | $80.24M | $40.20M | $22.85M | $16.55M | $14.42M |
| Short-term debt | $2.94M | $2.68M | $2.47M | $1.89M | $1.87M | $2.50M | $0 | $2.93M | N/A | N/A |
| Long-term debt | $168.65M | $167.77M | $0 | N/A | N/A | $35.53M | $0 | N/A | $0 | $0 |
| Shareholder equity | $393.52M | $337.29M | $297.90M | $268.20M | $254.15M | $172.57M | $148.14M | $130.24M | $109.77M | $87.50M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $656.03M | $640.55M | $629.53M | $615.69M | $598.07M | $577.59M | $556.01M | $551.82M | $377.02M | $363.08M | $353.96M | $346.78M |
| Total liabilities | $223.90M | $220.21M | $222.90M | $222.17M | $219.15M | $214.91M | $208.43M | $214.53M | $45.95M | $43.55M | $45.45M | $48.88M |
| Cash and equivalents | $27.49M | $26.63M | $26.85M | $28.24M | $25.49M | $27.18M | $25.34M | $25.61M | $21.00M | $22.27M | $26.59M | $24.27M |
| Shareholder equity | $432.13M | $420.34M | $406.62M | $393.52M | $378.92M | $362.69M | $347.57M | $337.29M | $331.07M | $319.53M | $308.50M | $297.90M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 91.7% of operating cash flow. Dividends and share repurchases together came to 26.8% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $81.25M | $44.12M | $36.75M | $25.38M | $35.10M | $34.80M | $14.18M | $19.51M | $22.87M | $16.90M |
| Capital expenditures | $6.78M | $6.96M | $7.26M | $3.23M | $4.88M | $2.98M | $3.76M | $3.05M | $6.42M | $2.84M |
| Free cash flow | $74.47M | $37.16M | $29.49M | $22.15M | $30.22M | $31.82M | $10.42M | $16.45M | $16.45M | $14.05M |
| Dividends paid | $18.11M | $14.38M | $12.45M | $10.99M | $9.34M | $7.70M | $6.74M | $5.45M | $4.18M | $3.32M |
| Share repurchases | $1.82M | $1.72M | $853.00K | $642.00K | $802.00K | $570.00K | $683.00K | $741.00K | $778.00K | $311.00K |
| Investing cash flow | -$64.94M | -$200.12M | -$24.71M | -$10.37M | -$61.08M | -$52.89M | -$24.10M | -$7.05M | -$28.96M | -$17.21M |
| Financing cash flow | -$14.54M | $158.10M | -$7.13M | -$9.23M | $13.70M | $32.16M | -$4.62M | -$4.42M | $80.00K | -$2.58M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $21.99M | $15.96M | $15.09M | $23.16M | $28.76M | $20.29M | $9.04M | $15.18M | $14.25M | $9.63M | $5.07M | $10.75M |
| Capital expenditures | $2.33M | $2.31M | $2.78M | $1.78M | $2.28M | $1.34M | $1.38M | $2.04M | $1.67M | $1.88M | $1.37M | $1.28M |
| Free cash flow | $19.66M | $13.65M | $12.31M | $21.38M | $26.48M | $18.95M | $7.66M | $13.14M | $12.58M | $7.75M | $3.70M | $9.47M |
Frequently Asked Questions About LMAT
What is LeMaitre Vascular's annual revenue?
LeMaitre Vascular reported revenue of $249.60M for the fiscal year ended Dec 31, 2025.
How fast is LeMaitre Vascular's revenue growing?
Revenue was up 13.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 15.6%.
Is LeMaitre Vascular profitable?
Yes. LeMaitre Vascular reported net income of $57.73M for the fiscal year ended Dec 31, 2025, with a net margin of 23.1%.
How much free cash flow does LMAT generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $81.25M minus capital expenditures of $6.78M produced free cash flow of $74.47M.
How much debt does LeMaitre Vascular have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $168.65M, short-term debt of $2.94M and cash and equivalents of $28.24M.
LMAT pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts